RCEL Avita Medical, Inc. - Common Stock
Sobre Avita Medical, Inc. - Common Stock Visão geral da empresa da Wikipedia
Avita Medical is a clinical and commercial company developing and marketing a range regenerative medicine products. The first regenerative medicine product brought to the market by Avita Medical was ReCell spray-on skin for the treatment of burns. The two latest products are ReNovaCell, for Aesthetics and Plastic applications including skin trauma, and ReGenerCell for the treatment of chronic wounds. The Avita Medical regenerative product range is currently marketed in Europe, the Middle East, Africa (EMEA) and Australia.
Ler mais
Avita Medical is a clinical and commercial company developing and marketing a range regenerative medicine products. The first regenerative medicine product brought to the market by Avita Medical was ReCell spray-on skin for the treatment of burns. The two latest products are ReNovaCell, for Aesthetics and Plastic applications including skin trauma, and ReGenerCell for the treatment of chronic wounds. The Avita Medical regenerative product range is currently marketed in Europe, the Middle East, Africa (EMEA) and Australia.
Company history
Originally named "Clinical Cell Culture" and listed on the ASX under the symbol "C3", the company restructured under the name "Avita Medical" in June 2008. In 2015, the company conducted a strategic divestment of its respiratory business, including the Breath-a-Tech and Funhaler products, to support focus on its regenerative products.
Avita Medical is traded both on the Australian stock market under the ticker symbol AVH and on the American OTC stock market under the ticker symbol AVMXY.
ReCell, spray-on skin
ReCell is a device that enables clinicians to treat wounds and skin defects using very small samples of the patient's own cells. The procedure is performed on site at bedside and takes approximately 25 minutes to complete and does not require laboratory facilities, off-site culture of tissues or specialized staff. ReCell is approved in EMEA countries, China, and Australia and is in Pivotal/PIII trials in the US for burns as a first indication and a Pilot/PII US study underway for scars.
February 12, 2018 AVITA Medical announced that the U.S. Food and Drug Administration (FDA) has approved a significant increase in the number of patients who may be treated in the United States with the ReCell Autologous Cell Harvesting Device under a FDA Compassionate Use Investigational Device Exemption (IDE) program. Under the expanded protocol, up to 88 patients with life-threatening injuries, including severe burns, may be treated with ReCell. This is the fifth expansion to the Compassionate Use protocol for ReCell approved by the FDA and expands by 20 the number of patients who may be treated. Eligible patients are those who have insufficient healthy skin available for standard skin grafting treatment of their injuries and whose treating physicians believe there to be no suitable alternative treatment.
In October 2017, Avita Medical started to raise a goal of $17 million in capital for the product. The company worked with the Biomedical Advanced Research and Development Authority (BARDA) to raise money toward commercializing the product on the U.S. market.
September 28, 2017 Avita Medical announced submission of U.S. FDA Premarket Approval (PMA) Application for the ReCell device for treatment of burn injuries. The PMA submission includes clinical data from the two U.S. randomized, controlled trials with combined enrollment of 131 patients at twelve leading burn centers across the United States. The later trial demonstrated over 30% reduction in donor skin harvesting while achieving comparable near-term healing and long-term scar outcomes for treatment of third-degree burn injuries. Results from the earlier trial demonstrate a 97.5% reduction in donor skin harvested for treatment of second-degree burn injuries. The submission also includes a review of 55 cases of compassionate use of ReCell for extensive burn injuries.
September 21, 2017 Avita Medical announced the execution of an expanded contract option valued at approximately US$24.3 million. This newly executed contract option establishes funding for key clinical and health economics research in U.S. pediatric burn care and extends Avita's Project Bioshield contract through to September 2022. Avita Medical has had a strong relationship with BARDA since the execution of a five-year contract in September 2015. Under the base contract BARDA made an initial investment of US$16.9 million to support Avita's ongoing U.S. clinical regulatory program towards FDA Premarket Approval (PMA), and to procure 5,000-plus ReCell devices. The contract also allowed BARDA to exercise future options to support additional clinical trials, and provide surge capacity for up to another 20,000 ReCell devices. Supplemental funding worth up to US$7.96 million was also provided to Avita under the contract in June 2016, to provide further operational support to Avita's PMA preparation and Compassionate Use program.
On September 20, 2018, Avita Medical's ReCell wound care device received FDA PMA approval.
US Government grant
In 2009 the United States Armed Forces Institute of Regenerative Medicine provided Avita with a US$1.45 million grant to hasten the approval of the ReCell kit with the U.S. Food and Drug Administration.
Necrotizing fasciitis
In 2018 a burn center in Phoenix, Arizona held a press conference to discuss the ongoing results of using ReCell to treat a woman with flesh-eating bacteria also known as necrotizing fasciitis.
== References ==
Fonte: Wikipedia (Inglês), CC BY-SA 4.0 · Ver na Wikipedia ↗
RCEL Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas
RCEL Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização
Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS
Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?
Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC
Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial
Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos
Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber
RCEL Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta
- Compra forte 2 20,0%
- Compra 5 50,0%
- Manter 3 30,0%
- Venda 0 0,0%
- Venda forte 0 0,0%
Preço-alvo de 12 meses
3 analistas · 2026-08-13Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados
| Período | EPS Actual | EPS est. | Surpresa |
|---|---|---|---|
| 30 de Junho de 2026 | $-0.25 | $-0.29 | 0.04% |
| 31 de Março de 2026 | $-0.35 | $-0.29 | -0.06% |
| 31 de Dezembro de 2025 | $-0.38 | $-0.34 | -0.04% |
| 30 de Setembro de 2025 | $-0.46 | $-0.29 | -0.17% |
| 30 de Junho de 2025 | $-0.38 | $-0.25 | -0.13% |
| 31 de Março de 2025 | $-0.53 | $-0.39 | -0.14% |
Comparação de pares (subindústria GICS) Métricas chave vs pares do setor
| Ticker | Capitalização de Mercado | P/E | Receita YoY | Margem Líquida | ROE | Margem Bruta |
|---|---|---|---|---|---|---|
| RCEL | $105M | -2.0 | 11.5% | -67.8% | 328.9% | 82.1% |
| CNXU | — | — | — | — | — | — |
| GLSI | $300M | -14.7 | — | — | -2159.7% | — |
| PYXS | $72M | -0.9 | -14.2% | -574.5% | -112.9% | — |
| TARA | $286M | -4.0 | — | — | -33.7% | — |
| AKBA | $427M | -80.5 | 47.5% | -2.3% | -17.3% | — |
| ALEC | $172M | -1.1 | -79.1% | -679.2% | -280.7% | — |
| EBS | $644M | 13.3 | -28.8% | 7.1% | 9.9% | — |
| ARCT | $174M | -2.6 | -46.1% | -80.2% | -29.6% | — |
Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa
Demonstração de Resultados 17
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $72M | $64M | $50M | $34M | · | $14M | $5M | |
| Cost of Revenue | $13M | $9M | $8M | $6M | · | $3M | $1M | |
| Gross Profit | $59M | $55M | $42M | $28M | · | $11M | $4M | |
| R&D Expense | $21M | $20M | $21M | $14M | · | $9M | $8M | |
| SG&A Expense | $27M | $33M | $28M | $23M | · | $33M | $15M | |
| Operating Expenses | $101M | $112M | $86M | $59M | · | $58M | $36M | |
| Operating Income | $-43M | $-57M | $-43M | $-28M | · | $-43M | $-26M | |
| Interest Expense | $5M | $5M | $1M | $16.0K | · | $33.0K | $27.0K | |
| Other Non-op | $-1M | $163.0K | $8M | $892.0K | · | · | · | |
| Pretax Income | $-49M | $-62M | $-35M | $-27M | · | $-42M | $-25M | |
| Income Tax | $11.0K | $54.0K | $66.0K | $36.0K | · | $4.0K | $-121.0K | |
| Net Income | $-49M | $-62M | $-35M | $-27M | · | $-42M | $-25M | |
| EPS (Basic) | $-1.74 | $-2.39 | $-1.40 | $1.07 | · | $2.07 | $1.56 | |
| EPS (Diluted) | $-1.74 | $-2.39 | $-1.40 | $1.07 | · | $2.07 | $1.56 | |
| Shares (Basic) | 27,860,784 | 25,883,056 | 25,331,264 | 25,000,180 | · | 20,290,966 | 16,064,588 | |
| Shares (Diluted) | 27,860,784 | 25,883,056 | 25,331,264 | 25,000,180 | · | 20,290,966 | 16,064,588 | |
| EBITDA | $-40M | $-55M | $-42M | $-27M | · | · | · |
Balanço Patrimonial 26
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $10M | $14M | $22M | $18M | $56M | $74M | $20M | |
| Short-term Investments | $8M | $22M | $67M | $61M | $30M | · | · | |
| Receivables | $9M | $12M | $8M | $4M | $3M | $2M | $1M | |
| Inventory | $7M | $7M | $6M | $2M | $2M | $1M | $742.0K | |
| Prepaid Expense | $1M | $2M | $2M | $2M | $1M | $990.0K | $1M | |
| Other Current Assets | · | · | $18.0K | $127.0K | $15.0K | $75.0K | $125.0K | |
| Current Assets | $35M | $57M | $104M | $87M | $92M | $78M | $24M | |
| PP&E (Net) | $9M | $10M | $2M | $1M | $1M | $1M | $1M | |
| Accum. Depreciation | $5M | $3M | $2M | $2M | $2M | $881.0K | $667.0K | |
| Intangibles | $6M | $6M | $487.0K | $465.0K | $443.0K | $364.0K | $225.0K | |
| Other Non-current Assets | $612.0K | $546.0K | $355.0K | $122.0K | $638.0K | $1.0K | $125.0K | |
| Total Assets | $56M | $80M | $112M | $98M | $116M | $82M | $26M | |
| Accounts Payable | $9M | $6M | $4M | $3M | $3M | $4M | $2M | |
| Current Liabilities | $63M | $20M | $13M | $11M | $9M | $8M | $4M | |
| Capital Leases | $2M | $3M | $2M | $306.0K | $918.0K | $2M | · | |
| Other Non-current Liabilities | · | · | · | · | $113.0K | $0 | $42.0K | |
| Total Liabilities | $73M | $75M | $62M | $13M | $11M | $10M | $5M | |
| Long-term Debt | $43M | $42M | · | · | · | · | · | |
| Total Debt | $43M | $42M | $40M | · | · | · | · | |
| Common Stock | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | |
| Paid-in Capital | $394M | $368M | $350M | $340M | $332M | $259M | $165M | |
| Retained Earnings | $-408M | $-360M | $-298M | $-263M | $-236M | $-195M | $-153M | |
| AOCI | $-1M | $-2M | $-2M | $8M | $8M | $8M | $8M | |
| Stockholders' Equity | $-17M | $4M | $49M | $85M | $105M | $72M | $21M | |
| Liabilities + Equity | $56M | $80M | $112M | $98M | $116M | $82M | $26M | |
| Shares Outstanding | 30,571,662 | 26,354,042 | 25,682,078 | 25,208,436 | 24,925,743 | 21,467,912 | 18,712,996 |
Fluxo de Caixa 16
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| D&A | $2M | $1M | $632.0K | $568.0K | · | $465.0K | $269.0K | |
| Stock-based Comp | $10M | $13M | $8M | $7M | · | $16M | $2M | |
| Amort. of Intangibles | $600.0K | $93.0K | $35.0K | $58.0K | · | $119.0K | $0 | |
| Other Non-cash | $6M | $-2M | $-12M | $9.0K | · | · | · | |
| Operating Cash Flow | $-31M | $-49M | $-38M | $-19M | · | $-23M | $-19M | |
| CapEx | $1M | $9M | $1M | $452.0K | · | $590.0K | $1M | |
| Investing Cash Flow | $12M | $37M | $2M | $-19M | · | $-847.0K | $-1M | |
| Debt Issued | · | · | $39M | · | · | · | · | |
| Net Debt Issued | · | · | $39M | · | · | · | · | |
| Stock Issued | $15M | · | · | · | · | $82M | $32M | |
| Net Stock Activity | $15M | · | · | · | · | · | · | |
| Financing Cash Flow | $15M | $4M | $40M | $900.0K | · | $77M | $30M | |
| Net Change in Cash | $-4M | $-8M | $4M | $-38M | · | $53M | $9M | |
| Taxes Paid | $15.0K | $41.0K | $44.0K | $17.0K | · | · | · | |
| Free Cash Flow | $-32M | $-58M | $-39M | $-20M | · | · | · | |
| Levered FCF | $-37M | $-63M | $-41M | $-20M | · | · | · |
Lucratividade 8
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 82.1% | 85.9% | 84.5% | 82.5% | · | · | · | |
| Operating Margin | -59.4% | -88.1% | -85.1% | -79.9% | · | · | · | |
| Net Margin | -67.8% | -96.3% | -70.6% | -77.5% | · | · | · | |
| Pretax Margin | -67.8% | -96.2% | -70.4% | -77.4% | · | · | · | |
| EBITDA Margin | -56.1% | -86.3% | -83.8% | -78.3% | · | · | · | |
| ROA | -71.4% | -64.6% | -33.7% | -24.9% | · | · | · | |
| ROE | 328.9% | -739.5% | -63.2% | -30.9% | · | · | · | |
| ROIC | -161.5% | -121.2% | -48.1% | -32.5% | · | · | · |
Liquidez e Solvência 5
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.6 | 2.8 | 7.9 | 8.2 | · | · | · | |
| Quick Ratio | 0.4 | 2.4 | 7.3 | 7.7 | · | · | · | |
| Debt / Equity | -2.6 | 9.4 | 0.8 | · | · | · | · | |
| LT Debt / Equity | 0.0 | 9.4 | 0.8 | · | · | · | · | |
| Interest Coverage | -8.5 | -10.6 | -37.3 | -1719.1 | · | · | · |
Eficiência 3
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.1 | 0.7 | 0.5 | 0.3 | · | · | · | |
| Inventory Turnover | 1.8 | 1.4 | 2.0 | 2.8 | · | · | · | |
| Receivables Turnover | 6.9 | 6.6 | 9.0 | 10.4 | · | · | · |
Taxas de Crescimento 2
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 11.5% | 28.1% | 45.7% | · | · | · | · | |
| Revenue CAGR 3Y | 27.7% | · | · | · | · | · | · |
Avaliação (TTM) 14
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $72M | $64M | $50M | $34M | · | $14M | · | |
| Net Income TTM | $-49M | $-62M | $-35M | $-27M | · | $-42M | · | |
| Market Cap | $105M | $337M | $352M | $166M | · | · | · | |
| Enterprise Value | $130M | $344M | $303M | · | · | · | · | |
| P/E | -2.0 | -5.4 | -9.8 | 6.2 | · | 14.8 | · | |
| P/S | 1.5 | 5.3 | 7.0 | 4.8 | · | · | · | |
| P/B | -6.3 | 75.0 | 7.2 | 2.0 | · | · | · | |
| P / Tangible Book | · | · | 7.3 | 2.0 | · | 9.1 | · | |
| P / Cash Flow | -3.4 | -6.9 | -9.3 | -8.7 | · | · | · | |
| P / FCF | -3.3 | -5.8 | -8.9 | -8.5 | · | · | · | |
| EV / EBITDA | -3.2 | -6.2 | -7.2 | · | · | · | · | |
| EV / FCF | -4.0 | -5.9 | -7.7 | · | · | · | · | |
| EV / Revenue | 1.8 | 5.3 | 6.0 | · | · | · | · | |
| Earnings Yield | -50.4% | -18.7% | -10.2% | 16.2% | · | 6.8% | · |
Demonstração de Resultados 17
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $22M | $19M | $18M | $17M | $18M | $19M | $18M | $20M | $15M | $11M | $14M | $14M | $12M | $11M | $9M | $9M | |
| Cost of Revenue | $4M | $4M | $3M | $3M | $3M | $3M | $2M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $2M | |
| Gross Profit | $18M | $16M | $14M | $14M | $15M | $16M | $16M | $16M | $13M | $10M | $12M | $12M | $10M | $9M | $8M | $8M | |
| R&D Expense | $5M | $6M | $6M | $4M | $5M | $6M | $5M | $5M | $5M | $5M | $7M | $4M | $5M | $5M | $3M | $4M | |
| SG&A Expense | $6M | $6M | $7M | $7M | $7M | $6M | $7M | $10M | $8M | $9M | $8M | $6M | $6M | $8M | $5M | $5M | |
| Operating Expenses | $25M | $25M | $25M | $23M | $26M | $28M | $26M | $30M | $29M | $27M | $25M | $21M | $21M | $19M | $15M | $14M | |
| Operating Income | $-7M | $-9M | $-10M | $-9M | $-11M | $-12M | $-10M | $-14M | $-16M | $-17M | $-12M | $-9M | $-11M | $-10M | $-6M | $-6M | |
| Interest Expense | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $10.0K | $7.0K | $4.0K | $-3.0K | $6.0K | |
| Other Non-op | $688.0K | $-395.0K | $20.0K | $-3M | $2M | $-791.0K | $-314.0K | $-1M | $2M | $-66.0K | $6M | $615.0K | $801.0K | $725.0K | · | · | |
| Pretax Income | $-8M | $-11M | $-12M | $-13M | $-10M | $-14M | $-12M | $-16M | $-15M | $-19M | $-7M | $-9M | $-10M | $-9M | $-5M | $-6M | |
| Income Tax | $33.0K | $-11.0K | $-16.0K | $15.0K | $4.0K | $8.0K | $19.0K | $-28.0K | $33.0K | $30.0K | $12.0K | $11.0K | $13.0K | $30.0K | $24.0K | $4.0K | |
| Net Income | $-8M | $-11M | $-12M | $-13M | $-10M | $-14M | $-12M | $-16M | $-15M | $-19M | $-7M | $-9M | $-10M | $-9M | $-5M | $-6M | |
| EPS (Basic) | $-0.25 | $-0.35 | $-0.37 | $-0.46 | $-0.38 | $-0.53 | $-0.44 | $-0.62 | $-0.60 | $-0.73 | $-0.28 | $-0.34 | $-0.41 | $-0.37 | $0.22 | $0.22 | |
| EPS (Diluted) | $-0.25 | $-0.35 | $-0.37 | $-0.46 | $-0.38 | $-0.53 | $-0.44 | $-0.62 | $-0.60 | $-0.73 | $-0.28 | $-0.34 | $-0.41 | $-0.37 | $0.22 | $0.22 | |
| Shares (Basic) | 30,749,894 | 30,540,872 | -53,153,774 | 28,393,445 | 26,367,548 | 26,253,565 | -51,498,934 | 25,983,929 | 25,760,278 | 25,637,783 | -50,512,301 | 25,401,754 | 25,239,723 | 25,202,088 | -49,916,057 | 25,006,995 | |
| Shares (Diluted) | 30,749,894 | 30,540,872 | -53,153,774 | 28,393,445 | 26,367,548 | 26,253,565 | -51,498,934 | 25,983,929 | 25,760,278 | 25,637,783 | -50,512,301 | 25,401,754 | 25,239,723 | 25,202,088 | -49,916,057 | 25,006,995 | |
| EBITDA | $-7M | $-8M | · | $-9M | $-11M | $-11M | · | $-14M | $-16M | $-17M | · | $-9M | $-11M | $-10M | · | $-6M |
Balanço Patrimonial 25
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $9M | $8M | $10M | $15M | $12M | $15M | $14M | $19M | $17M | $17M | $22M | $51M | $37M | $28M | $18M | $24M | |
| Short-term Investments | $2M | $6M | $8M | $8M | $3M | $11M | $22M | $26M | $37M | $51M | $67M | $9M | $29M | $45M | $61M | $61M | |
| Receivables | $10M | $10M | $9M | $9M | $11M | $12M | $12M | $10M | $9M | $7M | $8M | $6M | $6M | $5M | $4M | $4M | |
| Inventory | $5M | $6M | $7M | $7M | $8M | $8M | $7M | $6M | $7M | $7M | $6M | $4M | $3M | $3M | $2M | $2M | |
| Prepaid Expense | $2M | $1M | $1M | $2M | $2M | $2M | $2M | $3M | $3M | $4M | $2M | $3M | $2M | $1M | $2M | $1M | |
| Other Current Assets | · | · | · | · | · | · | · | · | $8.0K | $135.0K | · | $26.0K | $525.0K | $29.0K | $127.0K | $17.0K | |
| Current Assets | $28M | $32M | $35M | $41M | $36M | $48M | $57M | $64M | $73M | $86M | $104M | $74M | $77M | $83M | $87M | $92M | |
| PP&E (Net) | $8M | $8M | $9M | $10M | $10M | $10M | $10M | $9M | $7M | $4M | $2M | $2M | $2M | $1M | $1M | $1M | |
| Accum. Depreciation | $6M | $6M | $5M | $5M | $4M | $4M | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Intangibles | $5M | $5M | $6M | $5M | $5M | $5M | $6M | $590.0K | $545.0K | $542.0K | $487.0K | $459.0K | $456.0K | $461.0K | $465.0K | $449.0K | |
| Other Non-current Assets | $593.0K | $534.0K | $612.0K | $1M | $839.0K | $287.0K | $546.0K | $546.0K | $473.0K | $401.0K | $355.0K | $236.0K | $285.0K | $230.0K | $122.0K | $548.0K | |
| Total Assets | $48M | $52M | $56M | $64M | $58M | $70M | $80M | $81M | $88M | $97M | $112M | $81M | $86M | $93M | $98M | $100M | |
| Accounts Payable | $6M | $7M | $9M | $8M | $7M | $9M | $6M | $4M | $4M | $4M | $4M | $3M | $4M | $4M | $3M | $3M | |
| Current Liabilities | $69M | $67M | $63M | $62M | $63M | $23M | $20M | $17M | $14M | $12M | $13M | $12M | $14M | $11M | $11M | $10M | |
| Capital Leases | $2M | $2M | $2M | $2M | $2M | $3M | $3M | $3M | $3M | $3M | $2M | $2M | $1M | $1M | $306.0K | $405.0K | |
| Total Liabilities | $76M | $75M | $73M | $70M | $71M | $74M | $75M | $69M | $64M | $64M | $62M | $17M | $16M | $14M | $13M | $12M | |
| Long-term Debt | · | · | $43M | $42M | · | · | $42M | · | · | · | · | · | · | · | · | · | |
| Total Debt | $47M | $46M | · | $42M | $42M | $41M | · | $43M | $41M | $41M | · | · | · | · | · | · | |
| Common Stock | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | |
| Paid-in Capital | $400M | $396M | $394M | $393M | $374M | $371M | $368M | $364M | $359M | $353M | $350M | $347M | $344M | $342M | $340M | $338M | |
| Retained Earnings | $-427M | $-419M | $-408M | $-397M | $-384M | $-374M | $-360M | $-348M | $-332M | $-317M | $-298M | $-291M | $-282M | $-272M | $-263M | $-257M | |
| AOCI | $-82.0K | $648.0K | $-1M | $-1M | $-2M | $-413.0K | $-2M | $-2M | $-2M | $-3M | $-2M | $8M | $8M | $8M | $8M | $7M | |
| Stockholders' Equity | $-28M | $-23M | $-17M | $-7M | $-13M | $-5M | $4M | $12M | $24M | $33M | $49M | $63M | $69M | $78M | $85M | $88M | |
| Liabilities + Equity | $48M | $52M | $56M | $64M | $58M | $70M | $80M | $81M | $88M | $97M | $112M | $81M | $86M | $93M | $98M | $100M | |
| Shares Outstanding | 30,926,847 | 30,776,689 | 30,571,662 | 30,493,111 | 26,613,678 | 26,434,658 | 26,354,042 | 26,217,629 | 25,949,906 | 25,789,051 | 25,682,078 | 25,550,694 | 25,447,615 | 25,327,761 | 25,208,436 | 25,030,902 |
Fluxo de Caixa 13
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $605.0K | $627.0K | $700.0K | $574.0K | $552.0K | $521.0K | $409.0K | $310.0K | $204.0K | $203.0K | $187.0K | $164.0K | $146.0K | $135.0K | $130.0K | $138.0K | |
| Stock-based Comp | $2M | $1M | $1M | $3M | $3M | $3M | $3M | $4M | $4M | $3M | $2M | $2M | $1M | $3M | $1M | $1M | |
| Amort. of Intangibles | $196.0K | $204.0K | $160.0K | $153.0K | $152.0K | $135.0K | $36.0K | $23.0K | $17.0K | $17.0K | $9.0K | $9.0K | $8.0K | $9.0K | $8.0K | $8.0K | |
| Other Non-cash | · | $-1M | · | · | · | $335.0K | · | · | · | $-5M | · | · | · | $-3M | · | · | |
| Operating Cash Flow | $-3M | $-10M | $-5M | $-5M | $-10M | $-10M | $-8M | $-7M | $-13M | $-21M | $-11M | $-9M | $-9M | $-9M | $-3M | $-3M | |
| CapEx | $108.0K | $19.0K | $-674.0K | $934.0K | $524.0K | $221.0K | $2M | $4M | $3M | $1M | $296.0K | $502.0K | $299.0K | $284.0K | $70.0K | $104.0K | |
| Investing Cash Flow | $4M | $2M | $11.0K | $-5M | $7M | $11M | $2M | $7M | $12M | $15M | $-57M | $22M | $18M | $19M | $-3M | $-8M | |
| Stock Issued | · | · | $0 | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $437.0K | $6M | $248.0K | $14M | $559.0K | $363.0K | $1M | $1M | $849.0K | $631.0K | $39M | $600.0K | $171.0K | $171.0K | $899.0K | $0 | |
| Net Change in Cash | $830.0K | $-2M | $-5M | $3M | $-3M | $820.0K | $-5M | $1M | $501.0K | $-5M | $-29M | $13M | $9M | $10M | $-6M | $-11M | |
| Taxes Paid | · | · | · | · | · | · | $20.0K | $2.0K | $19.0K | $17.0K | $0 | $0 | $44.0K | $9 | $0 | $0 | |
| Free Cash Flow | · | $-10M | · | · | · | $-11M | · | · | · | $-22M | · | · | · | $-9M | · | · | |
| Levered FCF | · | $-12M | · | · | · | $-12M | · | · | · | $-23M | · | · | · | $-9M | · | · |
Lucratividade 8
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 81.9% | 81.7% | · | 81.3% | 81.2% | 84.7% | · | 83.7% | 86.1% | 86.4% | · | 84.5% | 81.2% | 84.2% | · | 83.2% | |
| Operating Margin | -31.6% | -45.7% | · | -53.6% | -60.5% | -63.9% | · | -70.6% | -102.8% | -155.0% | · | -68.2% | -95.0% | -93.9% | · | -63.2% | |
| Net Margin | -35.3% | -55.1% | · | -77.3% | -53.9% | -74.9% | · | -82.9% | -101.3% | -168.0% | · | -63.8% | -88.3% | -87.4% | · | -61.5% | |
| Pretax Margin | -35.2% | -55.2% | · | -77.2% | -53.8% | -74.8% | · | -83.0% | -101.1% | -167.8% | · | -63.8% | -88.2% | -87.1% | · | -61.4% | |
| EBITDA Margin | -31.6% | -42.5% | · | -53.6% | -60.5% | -61.1% | · | -70.6% | -102.8% | -153.1% | · | -68.2% | -95.0% | -92.7% | · | -63.2% | |
| ROA | -14.5% | -17.5% | · | -18.2% | -13.6% | -16.6% | · | -20.0% | -17.7% | -19.6% | · | -9.6% | -11.0% | -9.3% | · | -4.9% | |
| ROE | 37.6% | 76.5% | · | -474.3% | -180.0% | -99.0% | · | -43.1% | -33.3% | -33.9% | · | -11.5% | -12.9% | -10.5% | · | -5.4% | |
| ROIC | -36.6% | -38.3% | · | -25.6% | -38.0% | -32.1% | · | -25.2% | -24.1% | -23.3% | · | -14.8% | -16.3% | -12.8% | · | -6.5% |
Liquidez e Solvência 5
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.4 | 0.5 | · | 0.7 | 0.6 | 2.1 | · | 3.7 | 5.3 | 7.2 | · | 6.2 | 5.6 | 7.2 | · | 9.6 | |
| Quick Ratio | 0.3 | 0.4 | · | 0.5 | 0.4 | 1.6 | · | 3.2 | 4.6 | 6.3 | · | 5.6 | 5.2 | 6.8 | · | 9.2 | |
| Debt / Equity | -1.7 | -2.0 | · | -6.4 | -3.3 | -9.1 | · | 3.5 | 1.7 | 1.3 | · | · | · | · | · | · | |
| LT Debt / Equity | · | · | · | 0.0 | -3.3 | -9.1 | · | 3.5 | 1.7 | 1.3 | · | · | · | · | · | · | |
| Interest Coverage | -4.7 | -6.2 | · | -7.2 | -8.9 | -9.6 | · | -10.2 | -11.6 | -12.7 | · | -930.6 | -1595.0 | -2477.8 | · | -958.0 |
Eficiência 3
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.3 | · | 0.2 | 0.3 | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 0.6 | 0.5 | · | 0.5 | 0.5 | 0.4 | · | 0.6 | 0.4 | 0.3 | · | 0.7 | 0.9 | 0.7 | · | 0.8 | |
| Receivables Turnover | 2.0 | 1.8 | · | 1.8 | 1.8 | 1.9 | · | 2.4 | 2.1 | 1.9 | · | 2.9 | 2.4 | 2.6 | · | 3.1 |
Avaliação (TTM) 14
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $76M | $73M | · | $74M | $72M | $64M | · | $59M | $52M | $47M | · | $45M | $40M | $36M | · | $32M | |
| Net Income TTM | $-41M | $-48M | · | $-53M | $-55M | $-64M | · | $-59M | $-53M | $-47M | · | $-34M | $-31M | $-31M | · | $-27M | |
| Market Cap | $128M | $114M | · | $156M | $141M | $215M | · | $281M | $206M | $413M | · | $373M | $433M | $354M | · | $132M | |
| Enterprise Value | $163M | $146M | · | $175M | $167M | $231M | · | $279M | $192M | $387M | · | · | · | · | · | · | |
| P/E | -2.9 | -2.2 | · | -2.6 | -2.5 | -3.3 | · | -4.7 | -3.8 | -8.7 | · | -16.2 | -54.9 | 29.1 | · | 4.8 | |
| P/S | 1.7 | 1.6 | · | 2.1 | 2.0 | 3.3 | · | 4.7 | 4.0 | 8.8 | · | 8.3 | 10.9 | 10.0 | · | 4.1 | |
| P/B | -4.6 | -4.9 | · | -23.4 | -10.9 | -47.1 | · | 23.0 | 8.6 | 12.7 | · | 5.9 | 6.3 | 4.6 | · | 1.5 | |
| P / Tangible Book | · | · | · | · | · | · | · | 24.2 | 8.8 | 12.9 | · | 6.0 | 6.3 | 4.6 | · | 1.5 | |
| P / Cash Flow | · | -11.3 | · | · | · | -20.9 | · | · | · | -19.8 | · | · | · | -39.0 | · | · | |
| P / FCF | · | -11.3 | · | · | · | -20.4 | · | · | · | -18.8 | · | · | · | -37.8 | · | · | |
| EV / EBITDA | -23.8 | -17.8 | · | -19.1 | -15.0 | -20.4 | · | -20.2 | -12.3 | -22.7 | · | · | · | · | · | · | |
| EV / FCF | · | -14.4 | · | · | · | -21.9 | · | · | · | -17.6 | · | · | · | · | · | · | |
| EV / Revenue | 2.1 | 2.0 | · | 2.4 | 2.3 | 3.6 | · | 4.7 | 3.7 | 8.2 | · | · | · | · | · | · | |
| Earnings Yield | -34.9% | -46.5% | · | -38.9% | -40.3% | -30.5% | · | -21.4% | -26.3% | -11.5% | · | -6.2% | -1.8% | 3.4% | · | 20.7% |
Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos
Demonstração de Resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Receita | $72M | $64M | $50M | $34M | — |
| Margem Bruta % | 82.1% | 85.9% | 84.5% | 82.5% | — |
| Margem Operacional % | -59.4% | -88.1% | -85.1% | -79.9% | — |
| Lucro líquido | $-49M | $-62M | $-35M | $-27M | — |
| EPS Diluído | $-1.74 | $-2.39 | $-1.40 | $1.07 | — |
Balanço Patrimonial
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Dívida / Patrimônio Líquido | -2.6 | 9.4 | 0.8 | — | — |
| Índice de liquidez corrente | 0.6 | 2.8 | 7.9 | 8.2 | — |
| Índice de Liquidez Seca | 0.4 | 2.4 | 7.3 | 7.7 | — |
Fluxo de Caixa
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Fluxo de caixa livre | $-32M | $-58M | $-39M | $-20M | — |
Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos
Escolha as métricas que importam para você — clique no ➕ ao lado de qualquer linha em Fundamentos Completos acima.
Sua seleção é salva e acompanha você em todos os tickers.
Investidores institucionais (13F) 81 declarantes · $18.7M total · Em 30 de Junho de 2026
Instituições que relatam a posse desta ação em seu Formulário 13F trimestral da SEC. Apenas posições compradas; um único declarante pode aparecer duas vezes para opções separadas. Grandes posições de compra/venda compensatórias geralmente refletem market-making ou inventário protegido, não convicção direcional.
| Novas posições | Posições encerradas | Aumentou | Diminuído | Variação líquida de ações |
|---|---|---|---|---|
| 26 (0 vs trimestre anterior) | 23 (+10 vs trimestre anterior) | 26 (+5 vs trimestre anterior) | 17 (+3 vs trimestre anterior) | -39.7M |
Comparado a Q1 2026. Os registros do Formulário 13F da SEC devem ser feitos em até 45 dias após o final do trimestre, mais um pequeno período de tolerância para registrantes atrasados — trimestres ainda dentro desse período são ignorados em favor do par mais recente totalmente reportado.
| Instituição | Valor | Ações | % de 13F rastreado | Tipo |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $5.509.065 | 1.333.914 | 29,41% | Ações |
| VANGUARD GROUP INC | $4.326.172 | 1.253.963 | 23,10% | Ações |
| GEODE CAPITAL MANAGEMENT, LLC | $1.124.496 | 272.127 | 6,00% | Ações |
| VANGUARD FIDUCIARY TRUST CO | $753.320 | 182.402 | 4,02% | Ações |
| NewEdge Advisors, LLC | $615.085 | 148.931 | 3,28% | Ações |
| MACQUARIE GROUP LTD | $595.395 | 144.164 | 3,18% | Ações |
| STATE STREET CORP | $532.675 | 128.977 | 2,84% | Ações |
| Quantinno Capital Management LP | $434.674 | 105.248 | 2,32% | Ações |
| Divisadero Street Capital Management, LP | $413.000 | 100.000 | 2,20% | Ações |
| GOLDMAN SACHS GROUP INC | $316.924 | 76.737 | 1,69% | Ações |
| NORTHERN TRUST CORP | $284.090 | 68.787 | 1,52% | Ações |
| Qube Research & Technologies Ltd | $263.428 | 63.784 | 1,41% | Ações |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $250.881 | 60.746 | 1,34% | Ações |
| XTX Topco Ltd | $236.075 | 57.161 | 1,26% | Ações |
| BNP PARIBAS FINANCIAL MARKETS | $222.847 | 53.958 | 1,19% | Ações |
| BANK OF AMERICA CORP /DE/ | $213.384 | 51.667 | 1,14% | Ações |
| MARSHALL WACE, LLP | $203.304 | 49.226 | 1,09% | Ações |
| Nuveen Asset Management, LLC | $159.002 | 12.422 | 0,85% | Ações |
| FMR LLC | $134.287 | 32.515 | 0,72% | Ações |
| IEQ CAPITAL, LLC | $133.812 | 32.400 | 0,71% | Ações |
| THOMPSON DAVIS & CO., INC. | $128.402 | 31.090 | 0,69% | Ações |
| Jain Global LLC | $127.101 | 30.775 | 0,68% | Ações |
| AMERIPRISE FINANCIAL INC | $117.696 | 28.498 | 0,63% | Ações |
| Russell Investments Group, Ltd. | $115.863 | 28.054 | 0,62% | Ações |
| IHT Wealth Management, LLC | $101.599 | 24.600 | 0,54% | Ações |
| Squarepoint Ops LLC | $95.035 | 23.011 | 0,51% | Ações |
| R Squared Ltd | $94.506 | 22.883 | 0,50% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $92.512 | 22.400 | 0,49% | Opção de compra |
| BlackRock, Inc. | $90.174 | 21.834 | 0,48% | Ações |
| CITADEL ADVISORS LLC | $87.746 | 21.246 | 0,47% | Ações |
| Mariner, LLC | $81.090 | 19.634 | 0,43% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $65.254 | 15.800 | 0,35% | Opção de venda |
| CITADEL ADVISORS LLC | $65.254 | 15.800 | 0,35% | Opção de venda |
| Abel Hall, LLC | $65.167 | 15.779 | 0,35% | Ações |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $64.734 | 15.674 | 0,35% | Ações |
| MILLENNIUM MANAGEMENT LLC | $63.722 | 15.429 | 0,34% | Ações |
| GABELLI FUNDS LLC | $61.950 | 15.000 | 0,33% | Ações |
| nVerses Capital, LLC | $56.448 | 13.668 | 0,30% | Ações |
| China Universal Asset Management Co., Ltd. | $51.625 | 12.500 | 0,28% | Ações |
| Quadrature Capital Ltd | $48.854 | 11.829 | 0,26% | Ações |
| MERCER GLOBAL ADVISORS INC /ADV | $48.073 | 11.640 | 0,26% | Ações |
| Cerity Partners LLC | $41.259 | 9.990 | 0,22% | Ações |
| Vanguard Global Advisers, LLC | $40.201 | 9.734 | 0,21% | Ações |
| AlphaQuest LLC | $32.354 | 9.378 | 0,17% | Ações |
| Arax Advisory Partners | $29.542 | 7.153 | 0,16% | Ações |
| AQR CAPITAL MANAGEMENT LLC | $28.179 | 6.823 | 0,15% | Ações |
| RHUMBLINE ADVISERS | $27.302 | 6.611 | 0,15% | Ações |
| CWM, LLC | $19.632 | 5.306 | 0,10% | Ações |
| JONES FINANCIAL COMPANIES LLLP | $17.083 | 4.303 | 0,09% | Ações |
| Tower Research Capital LLC (TRC) | $9.387 | 2.273 | 0,05% | Ações |
| WELLS FARGO & COMPANY/MN | $9.003 | 2.180 | 0,05% | Ações |
| Optiver Holding B.V. | $5.856 | 1.418 | 0,03% | Ações |
| Integrated Wealth Concepts LLC | $5.157 | 1.249 | 0,03% | Ações |
| PNC Financial Services Group, Inc. | $3.444 | 834 | 0,02% | Ações |
| OSAIC HOLDINGS, INC. | $2.601 | 630 | 0,01% | Ações |
| UBS Group AG | $2.172 | 526 | 0,01% | Ações |
| Allworth Financial LP | $2.070 | 501 | 0,01% | Ações |
| MORGAN STANLEY | $1.966 | 476 | 0,01% | Ações |
| Essential Partners LLC | $1.788 | 433 | 0,01% | Ações |
| IFP Advisors, Inc | $1.689 | 409 | 0,01% | Ações |
| SBI Securities Co., Ltd. | $1.218 | 295 | 0,01% | Ações |
| JPMORGAN CHASE & CO | $808 | 190 | 0,00% | Ações |
| GAMMA Investing LLC | $785 | 190 | 0,00% | Ações |
| True Wealth Design, LLC | $608 | 147 | 0,00% | Ações |
| ROTHSCHILD INVESTMENT LLC | $491 | 119 | 0,00% | Ações |
| NISA INVESTMENT ADVISORS, LLC | $384 | 93 | 0,00% | Ações |
| Fortitude Family Office, LLC | $285 | 69 | 0,00% | Ações |
| EverSource Wealth Advisors, LLC | $264 | 64 | 0,00% | Ações |
| Farther Finance Advisors, LLC | $260 | 62 | 0,00% | Ações |
| Caitong International Asset Management Co., Ltd | $194 | 47 | 0,00% | Ações |
| Parallel Advisors, LLC | $165 | 40 | 0,00% | Ações |
| SJS Investment Consulting Inc. | $141 | 34 | 0,00% | Ações |
| Virtu Financial LLC | $101 | 24.482 | 0,00% | Ações |
| Wealth Enhancement Trust Services, Inc. | $99 | 24 | 0,00% | Ações |
| HRT FINANCIAL LP | $42 | 10.179 | 0,00% | Ações |
| JPL Wealth Management, LLC | $25 | 6 | 0,00% | Ações |
| Clearstead Advisors, LLC | $13 | 3 | 0,00% | Ações |
| Sunbelt Securities, Inc. | $11 | 3 | 0,00% | Ações |
| BARCLAYS PLC | $4 | 1 | 0,00% | Ações |
| Capital Analysts, LLC | $3 | 652 | 0,00% | Ações |
| ROYAL BANK OF CANADA | $0 | 56 | 0,00% | Ações |
Executivos da empresa 20 insiders · 11 diretores · 11 conselheiros
| Investidor com informação privilegiada | Função | Última atividade | Ações detidas | Compras 12m | Vendas 12m | Líquido 12m |
|---|---|---|---|---|---|---|
| Cary Guy Vance | President and CEO | 29 de Maio de 2026 A | 40.771 | 0 | 0 | $0 |
| James Corbett | CEO | 21 de Janeiro de 2025 A | 11.580 | 0 | 0 | $0 |
| David D O'Toole | CFO | 12 de Junho de 2026 A | 152.927 | 5 | 0 | $47.094 |
| Sean Ekins | Interim CFO | 6 de Junho de 2023 A | 5.000 | 0 | 0 | $0 |
| Michael Holder | Chief Financial Officer | 1 de Julho de 2022 A | 46.450 | 0 | 0 | $0 |
| David Mcintyre | Chief Financial Officer | 17 de Julho de 2020 P | 893 | 0 | 0 | $0 |
| Kathy M. Mcgee | Chief Operating Officer | 1 de Julho de 2022 A | 46.450 | 0 | 0 | $0 |
| Nicole Kelsey | Chief Legal Officer | 18 de Fevereiro de 2026 A | 98.390 | 0 | 0 | $0 |
| Donna Shiroma | General Counsel | 31 de Maio de 2024 A | 45.951 | 0 | 0 | $0 |
| Andrew Quick | Chief Technology Officer | 6 de Junho de 2023 A | 46.450 | 0 | 0 | $0 |
| Erin Liberto | Chief Commercial Officer | 1 de Julho de 2022 A | 46.450 | 0 | 0 | $0 |
| Joseph Fralin Woody | Conselheiro | 9 de Junho de 2026 P | 107.961 | 5 | 0 | $104.900 |
| Suzanne Crowe | Conselheiro | 3 de Junho de 2026 A | 69.148 | 0 | 0 | $0 |
| Michael E Tarnoff | Conselheiro | 3 de Junho de 2026 A | 48.464 | 0 | 0 | $0 |
| Robert Mcnamara | Conselheiro | 20 de Janeiro de 2026 A | 108.985 | 2 | 0 | $95.000 |
| Jeremy Curnock Cook | Conselheiro | 20 de Janeiro de 2026 A | 62.050 | 0 | 0 | $0 |
| Jan Stern Reed | Conselheiro | 20 de Janeiro de 2026 A | 73.225 | 0 | 0 | $0 |
| Lou Panaccio | Conselheiro | 21 de Janeiro de 2025 A | 56.428 | 0 | 0 | $0 |
| Michael S Perry | Conselheiro | 21 de Novembro de 2022 M | 229.543 | 0 | 0 | $0 |
| Louis Drapeau | Conselheiro | 22 de Dezembro de 2021 A | 4.689 | 0 | 0 | $0 |
Executivos de declarações SEC Formulário 3/4/5; líquido = apenas P/V de mercado aberto
Participação em ETFs Detido por 10 ETFs
O peso reflete apenas participações diretas em ações (N-PORT); fundos alavancados ou baseados em derivativos podem deter exposição adicional a swaps não mostrada.
| Fundo | Peso | Unidades | Em | Fonte |
|---|---|---|---|---|
| IWC · iShares Trust | 0,03% | 108.036 SH | 8 de Agosto de 2026 | Diário |
| GSSC · Goldman Sachs ETF Trust | 0,01% | 18.465 NS | 31 de Maio de 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,00% | 3.453 NS | 31 de Maio de 2026 | N-PORT |
| RSSL · Global X Funds | 0,00% | 5.475 NS | 30 de Abril de 2026 | N-PORT |
| ITWO · ProShares Trust | 0,00% | 663 NS | 31 de Maio de 2026 | N-PORT |
| UWM · ProShares Trust | 0,00% | 517 NS | 31 de Maio de 2026 | N-PORT |
| URTY · ProShares Trust | 0,00% | 521 NS | 31 de Maio de 2026 | N-PORT |
| HDG · ProShares Trust | 0,00% | 13 NS | 31 de Maio de 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,00% | 341.039 SH | 8 de Agosto de 2026 | Diário |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 958.401 SH | 8 de Agosto de 2026 | Diário |